ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
Portfolio Pulse from
Alnylam Pharmaceuticals has announced its preliminary fourth-quarter and full-year 2024 product revenues. The company anticipates achieving adjusted operating income profitability by 2025.
January 13, 2025 | 5:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals has released preliminary revenue figures for Q4 and full-year 2024, with a positive outlook for profitability in 2025.
The announcement of preliminary revenues for 2024 and the expectation of profitability in 2025 is a positive signal for investors, indicating potential growth and financial stability.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100